Molecular Biology and Therapeutic Targets of Primitive Tracheal Tumors: Focus on Tumors Derived by Salivary Glands and Squamous Cell Carcinoma

Primary tracheal tumors are rare, constituting approximately 0.1–0.4% of malignant diseases. Squamous cell carcinoma (SCC) and adenoid cystic (ACC) account for about two-thirds these tumors. Despite most primary cancers being eligible surgery and/or radiotherapy, unresectable, recurrent metastatic may require systemic treatments. Unfortunately, the poor response to available chemotherapy as well lack other real therapeutic alternatives affects quality life outcome patients suffering from more advanced disease. In this condition, target therapy against driver mutations could constitute an alternative chemotherapy, help in disease control. The past two decades have seen extraordinary progress developing novel treatment options, shifting paradigm several such lung cancer. improvement knowledge regarding genetic biological alterations, major tumors, has opened up new perspectives, suggesting possible role targeted therapies rare purpose review is outline state molecular biology, preliminary data on treatments main focusing salivary-gland-derived squamous carcinoma.